Table 1 Availability of anti-malarials and malaria testing among all screened public sector outlets
From: The malaria testing and treatment landscape in mainland Tanzania, 2016
| Â | Public health facility % CI | Private not for-profit facility % CI | Public sector total % CI |
|---|---|---|---|
NÂ =Â 341 | NÂ =Â 65 | NÂ =Â 406 | |
Any anti-malarial | 96.2 (89.0, 98.8) | 96.4 (79.5, 99.5) | 96.2 (90.0, 98.6) |
QA ACT | 92.0 (84.0, 96.2) | 65.8 (49.0, 79.4) | 89.1 (82.5, 93.5) |
non-QA ACT | 13.3 (7.5, 22.5) | 29.8 (17.1, 46.7) | 15.1 (9.3, 23.6) |
SP | 51.5 (40.3, 62.6) | 54.1 (36.9, 70.4) | 51.8 (41.5, 61.9) |
Oral Quinine | 4.6 (1.8, 11.3) | 51.4 (33.9, 68.6) | 9.7 (6.3, 14.6) |
Other non-artemisinin therapy (amodiaquine and parenteral quinine) | 9.7 (6.5, 14.2) | 9.3 (3.7, 21.4) | 9.7 (6.7, 13.9) |
Artesunate injection | 71.4 (62.9, 78.5) | 24.9 (16.0, 36.6) | 66.3 (57.8, 73.8) |
Any malaria testing | 91.8 (85.6, 95.4) | 97.1 (80.6, 99.6) | 92.3 (86.7, 95.7) |
Malaria microscopy | 18.9 (13.3, 26.2) | 68.9 (54.1, 80.6) | 24.3 (18.2, 31.8) |
RDTs | 89.3 (82.2, 93.7) | 89.3 (77.4, 95.3) | 89.3 (82.9, 93.4) |
QA ACT and any malaria testing | 86.0 (77.9, 91.5) | 62.9 (46.4, 76.8) | 83.5 (76.4, 88.8) |
QA ACT no malaria testing | 5.9 (2.8, 12.1) | 2.9 (0.4, 19.4) | 5.6 (2.7, 11.2) |